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ABSTRACT
Two of the most important neglected tropical diseases, Chagas disease and leishmaniasis, are caused by 
protozoan intracellular parasites of the Trypanosomatida order. These infections provoke a high social 
burden and lead to the death of a large number of patients. The host triggers several immune mecha-
nisms, but in the absence of adequate treatment, the infection becomes chronic and in many cases causes 
the appearance of serious alterations. T lymphocytes are fundamental cells of the adaptive system and 
are the main immune elements that orchestrate the cell-to-cell response in the context of intracellular 
infections. Furthermore, it has been described that continuous and persistent stimulation in response 
to pathogenic antigens causes loss of antigen-specific functional capacities in the T cell subsets. This 
process is known as exhaustion. This review explores the results to date of the exhaustion process dur-
ing chronic infections caused by the trypanosomatid parasites Leishmania spp. and Trypanosoma cruzi. 
A large amount of evidence shows upregulation of the markers of the exhaustion process, namely, the 
inhibitory receptors, during these chronic infections. This increased expression is observed in both the 
CD4+ and CD8+ T cell populations. In parallel, with this increased expression of inhibitory receptors, the 
loss of antigen-specific functional capacity of these T cells is detected, reducing the lymphoproliferative 
potential and the ability to produce protective molecules against these parasitic infections, such as Th1-
like cytokines, among others. Additionally, a positive correlation between the high coexpression of these 
inhibitory molecules and the severity of the pathology is demonstrated. Furthermore, T cell populations 
experience a phenotypic fluctuation in the course of these infections toward the predominance of effector 
memory subsets with a late or terminal differentiation state. This balancing in turn affects the functional 
capacity of the T cells and enriches the number of cells with senescent and apoptotic characteristics. 
Thus, it has been demonstrated the existence of an exhaustion process that affects key populations for the 
parasite control. However, the role of this process in the progression of the severity of these pathologies 
is still unknown.
The current drugs used to treat these neglected diseases seem to partially reverse this exhaustion pro-
cess, denoting a reduction in the high inhibitory receptor expression observed prior to chemotherapies. 
An improvement in the functional capacity of these T cell populations is also observed, which could be 
related to the reversion of the dysfunctional process. However, the efforts made to date to evaluate block-
ing therapies do not lead us to a promising conclusion. It will probably be necessary to test the simulta-
neous blockade of several pathways and to continue advancing the knowledge to verify their possible 
use as immunotherapy. It is therefore necessary to continue investigating how this process is triggered 
and to what extent it influences the appearance of the symptomatology of patients.
Keywords: Chagas disease; leishmaniasis; T-cell exhaustion process; inhibitory receptors; cytokines.
Artículo Especial 
Special Article
Correspondencia 
Correspondence
Manuel Carlos López
mclopez@ipb.csic.es
Financiación 
Fundings
This study was supported by the 
grants SAF2016-81003-R and 
SAF2016-80998-R from the Programa 
Estatal I+D+i (MINECO), the Network 
of Tropical Diseases Research RICET 
(RD16/0027/0005) and FEDER. Elena 
Pérez Antón was supported by PhD 
studentships from the FUNCCET 
(Fundación Canaria para el Control de 
las Enfermedades Tropicales).
Conflicto de interés 
Competing interest
The authors of no conflicts of interest 
whatsoever to declare.
Agradecimientos 
Acknowledgements
This publication is part of the PhD thesis 
of student Elena Pérez Antón at the 
University of Granada in the Biomedicine 
Program.
Received: 23.05.2019 
Accepted: 24.05.2019
T-cell exhaustion process during chronic infection caused by intra-
cellular trypanosomatids
Proceso de agotamiento de las células T durante la infección crónica causada por 
tripanosomátidos intracelulares
Elena Pérez-Antón1, M. Carmen Thomas1, Adriana Egui1, Manuel Carlos López1
1 Instituto de Parasitología y Biomedicina López Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, España.
http://dx.doi.org/10.30827/ars.v60i2.9432
66 Ars Pharm. 2019; 60(2): 65-78
Pérez-Antón E., Thomas M. C., Egui A., López M. C.
RESUMEN
La enfermedad de Chagas y la leishmaniasis, causadas por pará-
sitos protozoarios intracelulares del orden Trypanosomatida, son 
consideradas dos de las enfermedades tropicales desatendidas 
más importantes. Estas infecciones conllevan un alto desgaste so-
cial, provocando el deterioro de la salud de un gran número de 
pacientes e incluso su muerte. Los linfocitos T son células funda-
mentales del sistema adaptativo y son los principales elementos 
inmunitarios para el control de estas infecciones intracelulares.
La presente revisión explora los estudios y resultados obtenidos 
hasta la fecha del proceso de agotamiento celular durante las in-
fecciones causadas por los parásitos Leishmania spp. y Trypano-
soma cruzi. Así, se recoge que la persistente estimulación celular 
en respuesta a antígenos de estos patógenos conduce a un pro-
ceso de pérdida de la capacidad funcional antígeno-específica en 
las poblaciones de células T CD4+ y CD8+. Numerosos estudios 
muestran la existencia de una correlación directa entre el nivel de 
la co-expresión de receptores inhibitorios y la gravedad de estas 
patologías. Paralelamente, se detecta la pérdida de la capacidad 
funcional específica de antígeno de estas células T, lo que reduce su 
potencial linfoproliferativo y su capacidad de producir moléculas 
protectoras contra estas infecciones. Además, durante el curso de 
estas infecciones se observa un incremento de la frecuencia de cé-
lulas T de memoria efectora con un grado de diferenciación tardía 
o terminal. Este balanceo fenotípico, a su vez, afecta a la capacidad 
funcional de las células T aumentando el número de células con ca-
racterísticas senescentes y apoptóticas. Así, los estudios realizados 
hasta la fecha demuestran con certeza la existencia de un proceso 
de agotamiento que afecta a poblaciones clave para el control pa-
rasitario. Sin embargo, actualmente se desconoce con precisión el 
papel que este proceso de agotamiento juega en el agravamiento 
de estas patologías.
Los medicamentos actuales usados para tratar estas enfermedades 
protozoarias revierten parcialmente este proceso de agotamiento. 
Así, tras el tratamiento, numerosos pacientes muestra una reduc-
ción en la expresión de receptores inhibitorios y co-expresión de 
los mismos. También se ha observado una mejoría en la capacidad 
funcional de las distintas poblaciones de células T, que podría es-
tar relacionada con la reversión del proceso disfuncional. Sin em-
bargo, los estudios realizados hasta la fecha en la evaluación de 
terapias de bloqueo de los receptores inhibitorios no han conduci-
do a resultados prometedores. Algunos autores proponen evaluar 
terapias de bloqueo simultáneo de varias vías de señalización, con 
el fin de ampliar el conocimiento sobre esta herramienta como po-
sible inmunoterapia de control de la infección por los mencionados 
parásitos. Además, se considera necesario continuar investigando 
sobre cómo se desencadena exactamente este proceso de agota-
miento celular y en qué medida influye en la aparición de la sin-
tomatología de los pacientes y ausencia de control de la infección.
Palabras clave: Enfermedad de Chagas; leishmaniosis; proceso de 
agotamiento de células T; receptores inhibitorios; citoquinas.
INTRODUCTION
The trypanosomatids Trypanosoma cruzi and Leishmania 
spp. are intracellular protozoan parasites that are causative 
agents of Chagas disease and leishmaniasis, respectively. 
Both diseases are considered neglected tropical diseases 
causing high morbidity and mortality, with approximate-
ly 8,000 and 20,000-50,000 deaths per year, respectively(1, 2). 
The vectors transmitting T. cruzi infection are endemic to 
Latin America, where approximately 70 million people are 
at risk of infection, and it is estimated that 7 to 10 million 
are currently infected. Leishmaniasis is widely distributed 
in 98 countries, where approximately 12 million people are 
infected and 1.5 to 2 million new cases are detected each 
year. Migratory flows around the world are changing the 
epidemiology of these diseases, spreading and globalizing 
them(3, 4).
Leishmaniasis is a disease or a group of diseases caused 
by the infection of protozoa of the genus Leishmania. The 
different clinical outcomes are determined in part by the 
Leishmania infecting species, which can remain localized 
in the skin tissue causing chronic ulcers to develop on the 
skin (called cutaneous leishmaniasis [CL]) or can dissemi-
nate from the site of skin infection to visceral organs where 
they can cause the most fatal disorder, namely, visceral 
leishmaniasis (VL). Additionally, there are a number of less 
normal forms, including mucocutaneous (ML) and diffuse 
(DCL) forms of CL and post-kala-azar dermal leishmania-
sis (PKDL)(5). Chagas disease shows an initial short acute 
phase, usually characterized by nonspecific symptoms (fe-
ver, swollen lymph nodes, headaches, etc). Patients with-
out treatment develop a chronic phase in which they can 
remain for decades without evident symptoms, in a stage 
called indeterminate. From this phase, in 30-40% of the pa-
tients and by mechanisms not fully established, the disease 
progresses to a symptomatic stage characterized by cardi-
ac alterations as well as disorders in the digestive and/or 
nervous system(6).
Immune system modulation associated with intracellu-
lar trypanosomatid infections
The infections caused by Trypanosoma cruzi and Leishmania 
spp. trypanosomatid parasites trigger multiple immune 
mechanisms in their host to combat the pathogen. These 
mechanisms operate at the innate and adaptive levels, as 
well as on the humoral and cellular scale. Due to the main-
ly intracellular condition of these parasites, which replicate 
within the cells, the cell-mediated response of adaptive 
host immunity plays a critical role. This function is primar-
ily orchestrated by T lymphocytes, which recognize the 
parasite antigens and promote specific functions to control 
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the infection(7). The most direct anti-parasitic action of these 
T cell populations is driven primarily by antigen-specific 
CD8+ T cells that can recognize and destroy infected host 
cells by secretion of cytolytic molecules or by the Fas/FasL 
pathway(8, 9). CD8+ T lymphocytes with cytotoxic abilities, 
known as CTL, are essential to control the intracellular in-
fection but require the help provided by cross-priming of 
CD4+ T cells to reach the memory phenotype and be au-
tonomous in a secondary expansion following re-encounter 
with the antigen(10). In T. cruzi infections, the repertoire of 
CD8+ T cells is dramatically restricted, which is a particular 
phenomenon known as immunodominance. Interestingly, 
mice that developed immune responses against subdomi-
nant/cryptic CD8+ T-cell epitopes corresponding to the im-
munodominant antigen are significantly protected against 
T. cruzi infection(11). Furthermore, the fully activated CTL 
also depends on the T helper type 1 (Th1) cytokines that 
mainly produce CD4+ T cells. Antigen-specific T cells can 
produce networks of Th1-like cytokines, such as IFN-γ, 
TNF-α, IL-2, etc(12, 13) (scheme in Figure 1). It has been report-
ed that these Th1 cytokines, and not Th2-type cytokines, 
are beneficial for anti-parasitic action by helping CTL ac-
tivity and by activating macrophages for the elimination 
of intracellular parasites and thus disrupting the progres-
sion of the infection(14, 15). In addition, T cells that have a 
Th1 profile combined with cytotoxic functions, known as 
Tc1, develop a strong protective response in the immune 
control of parasites(16-18). Furthermore, the Th17 profile, de-
scribed more recently, exhibits a protective role against the 
parasite in the control of these parasite infections and helps 
to mitigate the outcome of the pathology(19-21). Additionally, 
it is important to mention that these mechanisms need a 
homeostatic environment to be beneficial and that the ex-
acerbation of the response does not cause tissue damage. 
Thus, a subset of CD4+ T cells known as regulatory T cells 
(Treg) are critical in this immunoregulatory function, but 
in the context of these intracellular protozoan infections, 
there are controversial results with respect to the role of 
Treg in infection control(22, 23). In addition, the apoptotic cell 
death occurring in immune cell populations and the loss in 
number and functionality of T- and B-lymphocytes during 
trypanosomatid-induced diseases is a paradigm referred to 
as “exhaustion”. In this process, the expression of relevant 
molecules, namely, inhibitory receptors, regulates the func-
tional activity of the host antigen-specific lymphocytes(24).
Figure 1: Schematic representation of the hypothesis of the anti-parasitic response carried out by activated antigen-specific T cells 
focused on the action of a cytotoxic CD8+ T cell and a helper CD4+ T cell. The apoptotic mechanisms that are triggered in the infected 
cell generated by cytolytic molecules, such as perforin and granzyme, or via the Fas/FasL pathway are represented. In turn, the environ-
ment of cytokines secreted by helper CD4+ T cells that activate the cytotoxic action of CD8+ T cells is shown.
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Inhibitory receptors, the hallmarks of the T-cell ex-
haustion process
Inhibitory receptors are molecules that regulate the func-
tionality of immune cells, such as the diverse populations 
of T lymphocytes. The signaling pathways of the multiple 
inhibitory receptors that exist influence several points: i) 
they constitute a coinhibitory signal opposite to the costim-
ulation necessary for cellular priming; ii) they modulate the 
functional capacity of the cell that receives its signal path-
way to maintain an immune-homeostatic environment; iii) 
they constitute a key element in the exhaustion process, in 
a context of continuous re-encounter with pathogenic an-
tigens, by reducing the functional capacity of the cells that 
coexpress these molecules(25).
Multiple inhibitory receptors have been described in T-cell 
populations. All of them are members of the immunoglob-
ulin superfamily, as are the costimulatory molecules. In this 
case, they present a tyrosine motif, an immune receptor ty-
rosine-based inhibitory motif (ITIM) and/or an immune re-
ceptor tyrosine-based switch motif (ITSM), whose signaling 
pathway inhibits the activation signal, mediated by ITAM, 
through dephosphorylation(26). Most likely, the most well-
known T-cell inhibitory receptors are programmed cell 
death 1 (PD-1) and cytotoxic lymphocyte-associated anti-
gen 4 (CTLA-4); however, T-cell immunoglobulin and mu-
cin-domain containing-3 (TIM-3), lymphocyte activation 
gene 3 (LAG-3), leukocyte immunoglobulin-like receptor 1 
(LIR-1), CD160, and 2B4, among others, are also described 
as coinhibitory molecules(27, 28). All of these inhibitory mol-
ecules induce their expression in the cell membrane after 
cell activation(29), so these markers are expressed by active 
cells and not in naïve cells(30). In addition, these molecules 
have one or more different ligands, such as PD-1 with PD-
L1 and PD-L2 (also known as B7-H1 and B7-DC, respec-
tively). Furthermore, some of these molecules even share 
their ligands with costimulatory receptors, as is the case of 
CTLA-4, which binds to CD80 and CD86 as its homologous 
costimulatory molecule, CD28; another example is LAG-3, 
which interrupts the TCR signaling pathway by binding to 
MHC class II(31) (scheme in Figure 2).
Figure 2: Scheme proposed to summarize the main coinhibitory and costimulatory signaling pathways. This figure represents the recep-
tor molecules and their corresponding ligands, whose signaling affects the functional activation/inhibition of T cells.
In the context of chronic infection, Wherry et al. described 
the importance of these inhibitory molecules as hallmarks 
of immune exhaustion in pathogenic antigen-specific T 
cells(32). This dysfunctional process begins and increases 
gradually with the upregulation of the expression and co-
expression of inhibitory receptors in the membrane of an-
tigen-specific T cells. The number of inhibitory pathways 
activated as well as the intensity of expression (molecules 
per cell) of each pathway in the T cell indicates the degree 
of exhaustion, since its signaling acts synergistically(33, 34). In 
addition, and in parallel, the progressive loss of functional 
capacities of T cells occurs, causing impairment of the anti-
gen-specific response that controls the infection. The loss of 
functional capability begins to be detected by the decrease 
in the ability to produce IL-2, affecting the lymphoprolif-
erative potential of exhausted cells. Thus, subsequently 
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there is a decrease in the production of cytotoxic molecules 
and the TNF-α and IFN-γ cytokines, being the secretion of 
IFN-γ the one that most persists in the exhaustion process 
(scheme in Figure 3). This process, first described in viral 
infections(35), in its final steps can cause apoptotic arrest of 
the exhausted cell. Recently, much progress has been made 
in understanding the exhaustion process in the context of 
parasitic chronic infections(24, 36). The present review has as 
one of its main objectives to compile advances to date about 
the exhaustion process during intracellular trypanosoma-
tid infections.
In visceral leishmaniasis (VL), it was shown that chronic 
Leishmania infection causes upregulation of the gene expres-
sion of several inhibitory receptors and some of their ligand 
molecules in experimental models. The mRNA expression 
of PD-1 and CTLA-4 significantly increases in splenic CD4+ 
T cells of hamsters chronically infected with L. donovani(37). 
Additionally, the evaluation of VL infection by L. infantum 
in an experimental dog model shows mRNA levels to be 
enhanced with the infection and with the progression of the 
pathology. The mRNA of PD-1, CTLA-4, TIM-3 and LAG3, 
as well as PD-L1 and PD-L2, was superior in infected sub-
jects, with especially (and statistically) higher levels in the 
symptomatic group than in asymptomatic and uninfected 
subjects(38). Moreover, a higher PD-1 surface expression in 
CD4+ and CD8+ from PBMC of infected dogs was found, 
with frequencies gradually increasing with the severity of 
the pathology(39). In addition, a negative correlation was 
detected between the reported data of the proliferative ca-
pacity and IFN-γ production of these T cell populations and 
the degree of pathology. Superior frequencies of PD-1+ and 
CTLA4+ were detected in CD4+ and CD8+ T cells from the 
spleen of chronically infected mice by L. donovani compared 
with subjects in acute infection and in uninfected controls(40). 
Furthermore, knowing that severely exhausted cells can 
be arrested by apoptosis, an evaluation of the exhaustion 
process detected that circulating and spleen lymphocytes 
of infected dogs show a significantly higher percentage of 
apoptosis than do those of the uninfected group(41). All the 
aforementioned results may demonstrate the existence of 
an exhaustion process of antigen-specific CD4+ and CD8+ T 
cells in the course of experimental VL caused by Leishmania 
species (L. infatum and L. donovani), which would be related 
to the progress of the pathology, being more notorious in 
dogs that present symptoms. This impairment of the im-
mune mechanisms that control the infection could be what 
leads to the pathological outcome.
The exhaustion process in VL was also evaluated in chronic 
human infection by L. donovani, finding similar data. High-
er mRNA expression of the PD-1 and CTLA-4 genes was 
detected in the spleen, whole PBMC and peripheral CD8+ T 
cells of VL patients than in healthy donors(42). Moreover, a 
higher frequency of CD8+ T cells expressing the inhibitory 
receptors CTLA-4 and PD-1 on their surface was also de-
tected in patients infected with L. donovani versus healthy 
donors(42). The evaluation of the surface expression of these 
coinhibitory molecules is fundamental because it is from 
this point where the cellular exhaustion process is trig-
gered. However, in the context of VL, there is an absence of 
studies that evaluate the coexpression of inhibitory recep-
tors, which would demonstrate more strongly whether this 
exhaustion process occurs by this mechanism.
Otherwise, the evaluation of T cells in patients with CL 
showed that after human infection with L. panamensis, there 
is an increase in the CD8+ T cells surface expression of in-
hibitory receptors CD160, 2B4, CTLA-4, PD-1 and TIM-3 
as well as their coexpression(43), with the highest level of 
expression and coexpression in the CD8+ T cell population 
of active CL patients compared with that in cured patients, 
individuals with a positive Montenegro test and healthy 
donors. Additionally, patients with active CL show a low-
er multifunctional response of Leishmania-specific CD8+ T 
cells than the other mentioned groups(43), demonstrating 
how the exhaustion process of CD8+ T cells in active pa-
tients reduces their response capacity and may mark the 
nonresolution of the infection. A comparative study be-
tween the functional response of CD8+ T cells in patients 
with localized CL or diffuse CL caused by L. mexicana 
shows that patients with diffuse CL have a poor cellular 
immune response leading to chronicity(44). In fact, these pa-
tients present an increase in PD-1 expression with a marked 
impairment of the antigen-specific response of CD8+ T cells 
characterized by low cytotoxicity, low lymphoproliferation 
and low IFN-γ production(44).
In the context of human T. cruzi infection, the expression 
of multiple inhibitory receptors in circulating CD8+ T cells 
was evaluated in the different stages of chronic Chagas dis-
ease. A statistical increase in the frequency of CD8+ T cells 
expressing the inhibitory receptors PD-1, CTLA-4, TIM-
3, CD160, 2B4 and LIR-1 on their surface was detected in 
patients with chronic Chagas disease compared to healthy 
donors. Furthermore, these frequencies were markedly su-
perior in patients with severe cardiac alterations, especial-
ly when the expression of CTLA-4, PD-1 and CD160 was 
observed(45, 46). In the subset of CD4+ T cells, the expression 
of LIR-1 and CTLA-4 was higher in chronic Chagas dis-
ease patients than in healthy subjects, and a marked pos-
itive correlation was detected between the frequency of 
CD4+CTLA-4+ T cells and the severity of the disease(45). Fur-
thermore, the importance of the work of Lasso et al. lies in 
the coexpression study of inhibitory receptors, since it is the 
coexpression on the cell membrane that supports the de-
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terioration of the functional response of antigen-specific T 
cells through the cell exhaustion process, as has been wide-
ly described in viral chronic infection(33, 35). Coexpression 
of inhibitory receptors was markedly superior in the CD8+ 
T cell population of patients with chronic Chagas disease 
compared to healthy donors, which means that chronic T. 
cruzi infection causes the T-cell exhaustion of this critical 
subset for the continuous activation of these cells against 
antigens of the pathogen. Furthermore, the level of coex-
pression was higher in CD8+ T cells of patients with severe 
cardiac pathology than in asymptomatic patients or those 
with mild cardiac pathology. These data indicate a posi-
tive correlation between the degree of the T-cell exhaustion 
process and the severity of Chagas disease pathology. This 
T-cell exhaustion process was also correlated with the mul-
tifunctional response of T. cruzi-specific CD8+ T cells. Thus, 
patients with mild pathology or absence of symptoms 
showed a higher multifunctional capacity, unlike patients 
who presented severe cardiac alterations that showed an 
impairment of the functional capacity(46) (scheme in Fig-
ure 3). Similar results were found in the subpopulation of 
CD4+CD8+ T cells, which presented higher levels of inhib-
itory receptor coexpression in chronic Chagas disease pa-
tients versus healthy donors, observing an upward trend in 
the exhaustion process according to the severity of the pa-
thology(47). These findings indicate that the deterioration of 
the functional abilities of circulating antigen-specific T cells 
would be associated with the progression of the chronic dis-
ease of Chagas toward a stage of greater severity. Recently, 
a highly functional, non-exhausted T cell response has been 
observed in a persistent murine experimental infection by 
T. cruzi, as an indication that exhausted T cell responses 
and compromised immunity are not the only possible out-
comes of a persistent infection(48). All these findings support 
the need to continue research in order to determine the role 
that “exhausted” T cells play in the progression of natural 
chronic Chagas disease, where T. cruzi persistence occurs 
during 20 to 30 years in an asymptomatic stage.
Figure 3: Hypothetical model that represents the course of the T cell exhaustion process. Cellular exhaustion begins with the coexpres-
sion of some inhibitory receptor molecules, and this coexpression gradually increases with the process, augmenting the divergence of 
expressed coinhibitory molecules and enhancing the number of molecules expressed per cell. In parallel, the exhausted cell starts to lose 
functional capabilities. First, there is a loss of the ability to express IL-2, and the cell reduces its lymphoproliferative potential. Subse-
quently, the cytotoxic capacities of the cell are reduced, and the ability to produce TNF-α is lost. Finally, the production of the cytokine 
IFN-γ is maintained until the severe exhaustion stages.
At the heart level, significantly elevated levels of mRNA 
of PD-1 and PD-L1, as well as a marked expression of PD-
L1, were found in mice infected with T. cruzi. Moreover, 
the evaluation of mouse heart-infiltrating T lymphocytes 
showed that CD4+PD-1+ and CD8+PD-1+ T cells constitute 
an extremely high percentage of infiltrating cell populations 
(88.0% and 98.6%, respectively)(49). Similar findings were 
detected by flow cytometry, discovering statistically supe-
rior PD-1 and PD-L1 expression in heart-infiltrated CD4+ 
and CD8+ T cells in chronically infected mice versus healthy 
controls(50). In chronic human T. cruzi infection, CTLA-
4 and PD-1 expression was detected in infiltrated cells of 
myocardial explants of patients with severe cardiomyopa-
thy(45, 51). It is worth mentioning that a significant number of 
CTLA-4+ T lymphocytes were found in areas with severe 
myocarditis and the presence of amastigotes. The authors 
stated that these findings support the conclusion that per-
sistent infection with T. cruzi leads to the upregulation of 
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inhibitory receptors, which could alter the parasite-specific 
T-cell response in the chronic phase of Chagas disease and 
might be another factor involved in disease progression(45).
Processes that modulate the functional activity of 
T-cell subsets associated with Leishmania and Trypa-
nosoma cruzi infections
During chronic Chagas disease and leishmaniosis, the 
modulation of several functional processes associated with 
T-cell subsets occurs (Scheme in Figure 4). CD4+ T cells 
from chronic Chagas disease patients with severe cardi-
ac symptoms exhibit signs of senescence, as measured by 
CD57 expression(52). Cutaneous (CL) and mucocutaneous 
leishmaniasis (ML) patients also show enhanced expres-
sion of the senescence marker CD57 in CD4+ and CD8+ T 
cells, conferring in the ML patients a superior frequency of 
CD8+CD57+, with senescent cells accounting for approxi-
mately 40% of the total CD8+ T cell compartment(53). The 
process of senescence is intimately linked with a poor pro-
liferative capacity of the cell. However, despite lymphop-
roliferative dysfunction, senescent cells are able to produce 
cytotoxic molecules and cytokines(54, 55). Thus, the CD8+ T 
cell subset from ML patients showed a higher expression 
of perforin(53). Furthermore, in effector memory T cells (TEM 
and TEMRA), in which it has been described that the senes-
cence process is more prevalent(56), CD57 expression was 
evaluated in CL patients. In this study, TEMRA cells from ac-
tive CL patients presented a higher number and frequency 
of CD8+CD57+ and CD4+CD57+ cells than did asymptomat-
ic individuals (with a positive Montenegro test) and cured 
patients(43).
The enrichment of T cells in the highest differentiation stag-
es was also described during Leishmania spp. and T. cruzi 
infections. The frequency of intermediately and late differ-
entiated CD4+ and CD8+ T cells was significantly superior 
in CL and ML patients compared with those detected in 
healthy donors(53). Conversely, the level of early differenti-
ated CD4+ and CD8+ T cells was detected at a significantly 
lower percentage in patients with CL and ML compared 
with healthy donors. Furthermore, an association between 
CD8+ T cell differentiation and the persistence of the Leish-
mania parasite was found, since there is a positive correla-
tion between the progression of the infection and the fre-
quency of late differentiated CD8+ T cells(53).
Chronic Chagas disease patients also present an enrich-
ment with cells in a late stage of differentiation compared 
to healthy donors(46, 57, 58), and the frequency of late differ-
entiated cells with senescence characteristics is greater in 
patients with severe heart disease(52). Moreover, a positive 
correlation between the degree of Chagas disease patholo-
gy and the stage of T-cell differentiation was also described 
in patients who presented the most advanced pathology, 
those who presented statistically superior numbers of late 
differentiation CD8+ T cells, and those who had inferior 
values of early differentiation CD8+ T cells(46). These dif-
ferentiation stages of CD8+ T cells are associated with the 
senescence process but are also related to a high or low an-
tigen-specific multifunctional capacity of the cells. In this 
way, late differentiated cells present a lower proliferative 
power and a mainly monofunctional profile, with a low-
er production of Th1-like cytokines and sometimes linked 
with an enhanced cytotoxic molecule expression(46, 52, 59).
On the other hand, T. cruzi chronic infection seems to af-
fect the phenotypic balance of the main T-cell subsets, 
mostly causing a balance towards a predominantly effec-
tor memory response, with enhanced frequency of effec-
tor memory T cells (TEM, CD45RA
-/CD45RO+CD27-CD28-
CCR7-) and terminal effector memory T cells (TEMRA o TTE, 
CD45RA+/CD45RO-CD27-CD28-CCR7-). The existing naïve 
T cell repertoire (CD45RA+/CD45RO-CD27+CD28+) is re-
duced, and in several chronic Chagas disease patients, a 
reduction of the central memory T cells (TCM, CD45RA
-/
CD45RO+CD27+CD28+CCR7+) has also been described(46, 57-
60). Furthermore, it has been reported that chronic Chagas 
disease patients show a gradual decrease in CD8+ TSCM cell 
frequency (CD45RA+CCR7+CD28+CD27+CD95+CD127+) 
associated with a severe state of the disease. In fact, anti-
gen-specific TSCM cells are not detectable in symptomatic 
patients with severe cardiac forms(59). The TSCM cells were 
described as an early differentiated and long-lived human 
memory T cell population with an improved capacity for 
self-renewal and multipotent ability to generate other sub-
sets of memory cells (central memory, effector memory and 
effector T cells) in response to antigen re-exposure(61). Thus, 
it is suggested that the decrease in cells with multiple effec-
tor functions and the lack of T cell population renewal may 
be associated with the clinical outcome of chronic Chagas 
disease.
CL and ML patients show a reduction in the frequen-
cy of naïve CD4+ and CD8+ T cells and increases in CD4+ 
and CD8+ TEM cells as well as CD8
+ TTE cells versus those 
in healthy donors(53). Moreover, patients with L. panamensis 
active CL show a higher frequency of TEMRA CD4
+ and CD8+ 
T cells and a lower number of naïve CD4+ and CD8+ T cells 
than do asymptomatic individuals with a positive Monte-
negro test(43). These results suggest that during Leishmania 
spp. infection, patients undergo an alteration of the T-cell 
subset pattern, resulting in an accumulation of terminal-
ly differentiated T cells and a low recruitment of naïve T 
cells (Scheme in Figure 4). This imbalance in T-cell subsets 
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could deteriorate or change the immune response and re-
sult in poor control of the infection. However, it has been 
shown that CD8+ T cells from patients with ML or CL pro-
duce more IFN-γ than healthy donors(53), which shows that 
in spite of the late phenotypic differentiation and partial 
senescence, CD8+ T cells maintain a critical function for the 
control of Leishmania infection.
Figure 4: Hypothesis related to progression of different cellular processes in the course of chronic infection by intracellular trypano-
somatids. Development of the processes of senescence, apoptosis, differentiation and phenotypic characterization, according to the 
presence or absence of infection, the progression of the illness and the presence of symptoms associated with the infection.
A positive trend toward a higher T-cell differentiation pro-
file has been reported in cells from coinfected CL and ML 
patients (Leishmania–T. cruzi) compared with mono-infect-
ed (Leishmania) patients. Moreover, the frequency of se-
nescent CD4+ and CD8+ CD57+ T cells was increased in T. 
cruzi-infected CL patients and CD8+CD57+ T cells in T. cru-
zi- infected ML patients versus single-infected patients(53). 
Additionally, in both groups coinfected with CL and ML, 
a lower expression of the CD127 marker was detected in 
CD4+ and CD8+ T cells compared to single-infected patients. 
Coinfected CL patients also showed a much lower frequen-
cy of naïve CD4+ and CD8+ T cells and superior numbers 
of terminal effector T cells, in both CD4+ and CD8+ T cells, 
compared with those found in CL patients. These authors 
suggest that this behavior could be due to an enhancement 
in antigenic stimulation produced by the action of both par-
asites in the host. Moreover, as CL patients present a short-
term infection, chronic T. cruzi infection might be the main 
cause of the highly differentiated T-cell phenotype(53).
Additionally, T cell populations during these trypanosoma-
tid chronic infections also exhibit signs of apoptotic arrest. 
Thus, CD4+ T cells from Chagas disease patients express 
superior caspase 3+ cells to those of healthy donors and 
have markedly increased expression in those patients with 
more severe cardiac symptoms(52). Likewise, higher levels 
of spontaneous apoptosis of CD8+ T cells (high level of An-
nexin V expression) have been reported in subjects with 
heart dysfunction compared with asymptomatic subjects 
and uninfected controls, consistent with a higher rate of 
terminally differentiated CD8+ T cells in patients with se-
vere cardiac dysfunction(57). Similarly, patients with visceral 
leishmaniasis (VL) show superior expression of Annexin 
V and Fas (CD95) in the T-cell populations of CD4+ and 
CD8+ lymphocytes(62). Higher levels of mRNA expression 
of apoptosis-inducing ligand genes (FasL in PBMC and of 
TRAIL in splenic aspirate cultures) were also detected in 
VL patients compared with healthy donors(42), associating 
it with a higher degree of apoptosis during Leishmania spp. 
infection. This increase in apoptotic cells could be related to 
the final steps of the exhaustion process that T cells under-
go during trypanosomatid infections, as has been reported 
in viral infections(63), although other unrelated factors could 
induce this programmed cell death.
Potential recovery of the T-cell functional response af-
ter chemotherapeutic treatment
Another important point that arises after knowing that the 
T-cell exhaustion process is undergone in these parasitic 
infections and compromises the functionality of the host’s 
immune system is whether the current anti-parasitic ther-
apies have any effect on this process (scheme in Figure 5). 
Therefore, a review of the evaluation of hallmarks of ex-
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haustion, namely, inhibitory receptors, and the study of the 
functionality of the T-cell subsets monitored before and af-
ter treatment is included below. Thus, a statistically signif-
icant drop in the mRNA of CTLA-4 and PD-1 from splenic 
aspirate culture cells and of PD-1 in PBMC was detected 
after treatment in VL patients. Additionally, the frequency 
of CD8+CTLA-4+ T cells decreased statistically after therapy 
in these VL patients(42). Likewise, the frequency of CD8+ T 
cells expressing CD160 was also significantly higher in pa-
tients with active CL than in patients cured by chemother-
apy. The same pattern of differences was found between 
this pair of patient groups for the frequency of CD8+ T cells 
that expressed 2B4 and PD-1, although the differences were 
not statistically significant(43). CD8+ T cells from cured pa-
tients showed a higher multifunctional capacity than those 
from patients with active CL. A multifunctional capacity of 
antigen-specific CD8+ T cells, which was only observed in 
cured patients, was indicated by the ability of the cells to si-
multaneously perform the five examined functions (IFN-γ+, 
TNF-α+, IL-2+, granzyme B+ and perforin+). Furthermore, 
cured patients showed a higher proportion of CD8+ T cells 
expressing three or four of these cytokines and cytotoxic 
molecules. Similarly, cured patients, in particular, showed 
a higher frequency of CD8+ T cells expressing IFN-γ+ and 
TNF-α+ than patients with active CL, suggesting a relevant 
role of these cytokines in the infection control(43). Further-
more, after treatment, VL patients markedly enhanced the 
production of IFN-γ+ against Leishmania antigens by CD8+ T 
cells, which was related to the protective immune response 
and infection control(42). In this context, the high production 
of IFNγ and TNF-α by CD8+ T cells and the greater pro-
portion of multifunctional CD8+ T cells observed in cured 
CL patients could be associated with the lower PD-1 ex-
pression found in these patients, which might be related 
to a partial reversion of the exhaustion process induced by 
treatment.
Remarkably, VL and CL patients show a reduction in the 
effector cytotoxic capacities of CD8+ and CD4+ T cells after 
treatment, with a significant decrease in the expression of 
perforin and granzyme A and B, as well as of the degranu-
lation marker CD170a(42, 43, 64). This decrease in cytotoxicity 
could be related to a drop in parasite load or the double 
role associated with CTL in Leishmania infection, which po-
tentiates the death of infected cells but is also associated 
with an advance in the pathology and of the tissue inju-
ry(65, 66). Moreover, after treatment, a relevant increase in the 
populations of naïve CD4+ and CD8+ T cells, concomitant 
with a slight reduction in the ratio of CD8+ TEMRA/TEM cells, 
was observed(43), which could be significant in the func-
tionality modifications detected after therapy. Addition-
ally, in the follow-up after anti-parasitic treatment of ML 
patients, who showed therapeutic success, they presented 
a predominance of early differentiated CD8+ T cells and a 
drop in the frequency of highly differentiated CD8+ T cells, 
whereas patients with frequent relapses (therapeutic fail-
ure) showed the opposite pattern(53).
In the context of chronic T. cruzi infection, a decrease in 
the coexpression of inhibitory receptors, such as 2B4, TIM-
3, PD-1 and CTLA-4, was observed by CD8+ T cells from 
asymptomatic patients associated with the trypanocidal 
treatment(67). In parallel, the multifunctional capacity of 
this subset of CD8+ T cells noticeably improves, increasing 
the cells expressing both the cytotoxic molecules (perfor-
in and/or granzyme) and the Th1-like cytokines (IFNγ, 
TNF-α and/or IL-2) against T. cruzi antigens(67). These find-
ings suggest that anti-parasitic treatment partially reduc-
es the cell exhaustion process in CD8+ T cells, enhancing 
the quality of the antigen-specific CD8+ T cell response. In 
this regard, other research studies based on follow-up af-
ter treatment have shown similar results, in which CD8+ T 
cells enhance their production of antigen-specific Th1-like 
cytokines (IFN-γ and TNF-α) after therapy(68, 69) (scheme in 
Figure 5). These modifications may improve the response 
against the parasite, which could mean better control of T. 
cruzi infection and could prevent the progression of chronic 
disease and the appearance of symptoms in asymptomatic 
patients. In this line, an evaluation of the exhaustion pro-
cess in the minority T cell population of CD4+CD8+ demon-
strated a reduction in the upregulated coexpression of in-
hibitory receptors after chemotherapy with benznidazole in 
chronic Chagas disease patients. This effect of the treatment 
was stronger in asymptomatic patients compared with 
those patients who present cardiac alterations. Additional-
ly, these findings were associated with an improvement in 
the multifunctional capacity of antigen-specific CD4+CD8+ 
T cells against T. cruzi antigens in vitro and were related to 
an increase in the subset of CD4+CD8high T cells, which are 
characterized by an active phenotype, and a reduction of 
the subset of CD4+CD8low T cells, which are associated with 
a senescent origin, with all of these modifications detected 
after therapy(47). Further, the evaluation of the impact of an-
ti-parasitic therapy detected in the CD4+ T cell population 
showed a reduction of the cells expressing the inhibitory 
receptor LIR-1 in the majority of chronic Chagas disease 
patients evaluated(45). A greater lymphoproliferative capac-
ity, with an increase in the production of Th1 (IFN-γ and 
TNF-α) and Th17 (IL-17) cytokines, was also described in 
the CD4+ T cell population after treatment(70). This improve-
ment in the quality of the T-cell subset response could facil-
itate the parasitic reduction and the nonprogression of the 
pathology observed after the treatment administration, as 
reported(71-74). However, the reduction of the parasitic load 
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produced by the treatment may also allow the improve-
ment of the immune response and the reduction of the ex-
haustion process of these T cells. Nevertheless, more stud-
ies are needed to clarify how immunomodulation caused 
by chemotherapy happens.
Figure 5: Diagram of the impact of anti-parasite therapies on 
different cellular processes of T cell subsets of chronic patients 
infected by T. cruzi or Leishmania spp. Effect of antiparasitic 
therapies on the expression of inhibitory molecules, the functional 
capacity of antigen-specific T cells, and the proportion of cells in 
different stages of differentiation and over the frequency of the 
naïve and TEMRA cell phenotypes.
Immune checkpoints, based on the blockade of inhib-
itory receptor pathways, analysis of their repercussion
Several studies have evaluated whether blocking certain 
signaling pathways of inhibitory receptors, principally 
PD-1 and CTLA-4, has a positive impact on the dysfunc-
tional processes that occur in the different T-cell popula-
tions during the course of Leishmania and T. cruzi chronic 
infections. However, most of them have been carried out 
in experimental infection models. In general, the report-
ed results suggest that the inhibition mediated by PD-1 
or CTLA-4 could be critical in the progression of the dis-
ease and the maintenance of the infection in the host, since 
blocking these pathways markedly reduces the parasitic 
load. This drop in parasitemia could be closely related to 
the improvement of the functional capacity of the T cells, 
achieving a less exhausted immune response and a great-
er propensity to optimal control of the infection. Some of 
these studies have demonstrated that the recovery of func-
tionality is greater in the CD4+ T cell population than in 
CD8+ T cells. In fact, CD8+ T cells improve their lymphopro-
liferation potential and survival, but most failed to restore 
cytokine production after blocking treatment(38, 39, 75). In viral 
infections, it has been described that CD8+ T cells undergo 
a more severe process of cellular exhaustion that occurs in 
other T-cell subsets; therefore, the recovery after blocking a single pathway may not be enough to restore their functional 
capabilities to a greater extent(32) (Scheme in Figure 6).
Figure 6: Representation of the possible impact of blocking therapies on exhaustion of T cells. This figure represents the difficulty of re-
versing the cell exhaustion process in the most advanced phases of the process, although the blocking therapy used is directed to several 
signaling coinhibitory pathways. On the other hand, therapies aimed at blocking a single inhibitory pathway may not achieve modifi-
cation of the functional capacity of the cells or achieve a perceptible improvement of any of the antigen-specific functions of partially 
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exhausted T cells. Thus, a therapy triggered at blocking multiple 
coinhibitory pathways can achieve a major reversal of the exhaus-
tion process, recovering to a greater degree the lost capabilities of 
specific-antigen T cells and obtaining an enhanced control of the 
infection, which can have an impact by decreasing the parasitic 
load after therapy.
The impact evaluation of inhibitory receptor blockade car-
ried out in vitro in a model of primary infection with L. ma-
jor in human cells showed that blocking the PD-1/PD-L1 
inhibitory pathway has a beneficial role for the infection 
control, finding a significant increase of antigen-specific T 
cells with enhanced functional abilities. The L. major-specif-
ic T cells with good lymphoproliferative capacities (CFSElow 
T cells) enrich their number significantly in the subset of 
CD4+ T cells and slightly in the population of CD8+ T cells. 
In addition, blockade of PD-1 leads the T-cell response to a 
Th1 profile, predominantly over Th2, increasing the anti-
gen-specific production of IFNγ and TNF-α and enhancing 
the frequency of CFSElow CD4+T-bet+ T cells, while decreas-
ing the number of CFSElow CD4+GATA3+ T cells. Additional-
ly, CFSElow CD4+ T cells improve their antigen-specific pro-
duction of important cytotoxic molecules, such as perforin, 
granulysin, granzyme A and B, after the blockade. All of 
these improved abilities in the T-cell subset after the block-
age occurred simultaneously with a drop in the infection 
rate of L. major(76). These results showed that the blockade of 
PD-1/PD-L1 could be beneficial for the control of Leishma-
nia infection. However, the blockade of PD-1 or CTLA-4 in 
PBMC and splenic aspirate cells from VL patients infected 
by L. donovani did not show an increase in IFN-γ production 
or a reduction in parasite load(42).
In the context of T. cruzi chronic experimental infection 
models, it was observed that systemic blood parasitemia 
decreases after treatment with αPD-1, associated with an 
increase in T. cruzi-specific immunoglobulin G1 levels due 
to blocking therapy(50). Recently, it has been reported that 
therapy based on the blockade of PD-1 failed to enhance 
the production of IFN-γ and/or TNF-α in CD8+ TEM cells 
after polyclonal ex vivo stimulation in muscle or spleen(48). 
However, few investigations that block these signaling 
pathways have been performed in cells from chronic Cha-
gas disease patients. In this context, it has been described 
that CTLA-4 blocking does not produce a quantitative in-
crease in antigen-specific IFN-γ production (45). These facts 
highlight the importance of conducting further studies 
based on the blockade of several inhibitory receptors si-
multaneously, which would reveal whether this approach 
could truly be an applicable immunotherapeutic strategy.
CONCLUSIONS
During chronic infections caused by intracellular trypa-
nosomatid parasites, such as Leishmania and Trypanosoma 
cruzi, there exists an exhaustion process undergone by the 
T-cell populations. This exhaustion process greatly affects 
the quality of the antigen-specific T-cell response against 
the parasite, which can worsen the infection control. A 
positive correlation between the intensity of this dysfunc-
tional process and the severity of the pathology has been 
described. All these assertions allow us to hypothesize that 
the exhaustion of the cell immune response could cause 
a breakdown of the host-parasite balance and triggering 
the pathology. Remarkably, the current therapies seem to 
partially reverse this process of exhaustion of the T-cell 
immune response while improving the quality of the an-
tigen-specific response to control the infection. Likewise, 
the blocking of these signaling pathways of the coinhib-
itory molecules, although it must continue to be evaluat-
ed, demonstrates a beneficial role, improving in part the 
functional capacity of the T cells and reducing parasitemia. 
However, not all investigations present this promising re-
sult after blocking therapies, since the individual blockade 
of some of these pathways shows no improvement in the 
response to the pathogen.
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